Advertisement

Clinical Significance of Tumor-Associated Antigens and Antitumor Antibodies in Human Malignant Melanoma

  • Rishab K. Gupta
  • Donald L. Morton

Abstract

The concept that an immune response similar to that of infectious diseases is elicited in patients suffering from malignancy is well established. This concept was first developed during the early 1900s when it was observed that transplantable neoplasms in randomly bred laboratory mice could induce a strong immunity. On the basis of these observations, it was hypothesized that immune defense could play an important role in controlling the growth of cancer in man. This hypothesis was supported by the following findings: (1) spontaneous regression of established tumor (Everson and Cole, 1966); (2) delayed recurrence of rapidly progressive disease after successful treatment of the primary tumor (Lewis and Kiryabwire, 1968); (3) association of lymphocyte and other cellular infiltration into tumor with an improved prognosis (Black et al., 1956); (4) presence of tumor cells in lymphatics, peripheral blood, pleural cavity, and operative wounds of patients without subsequent development of metastases (Griffiths, et al., 1973; Roberts et al., 1967); and (5) inhibition of tumor autotransplants when mixed with autologous leukocytes or plasma in almost half the patients studied (Southam et al., 1966).

Keywords

Melanoma Cell Melanoma Patient Human Malignant Melanoma Bacillus Calmette Guerin Spend Culture Medium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ax, W., Sedlacek, H. H., and Johennsen, R., 1976, Antigenic specificities of human melanoma cells in vitro: Detection by xenogeneic antisera and HLA isoantisera, Behring Inst. Mitt. 59: 71.Google Scholar
  2. Baldwin, R. W., and Robins, R. A., 1976, Interference with immunological rejection of tumors, Br. Med. Bull. 32:118.PubMedGoogle Scholar
  3. Baldwin, R. W., Bowen, J. G., and Price, M. R., 1973, Detection of circulating hepatoma D23 antigen and immune complexes in tumor bearer serum, Br. J. Cancer 28:16.PubMedGoogle Scholar
  4. Bennett, C., Cooke, K. B., and Geck, P., 1978, Protein insolubilization as an aid to the detection of melanoma antigen in human urine, Protides Biol. Fluids Proc. College 24:667.Google Scholar
  5. Black, M. M., Opler, S. R., and Speer, F. D., 1956, Structural representations of tumor-host relationship in gastric carcinoma, Surg. Gynecol. Obstet. 102:599.PubMedGoogle Scholar
  6. Bluming, A. Z., Vogel, C. L., Ziegler, J. L., and Kiryabwire, J. W. M., 1972, Delayed cutaneous sensitivity reaction to extracts of autologous malignant melanoma: A second look, J. Natl. Cancer Inst. 48:17PubMedGoogle Scholar
  7. Bodurtha, H. J., Chee, D. O., and Lancius, J. F., 1975, Clinical and immunological significance of human melanoma cytotoxic antibody, Cancer Res. 35:189.PubMedGoogle Scholar
  8. Bourgoin, J., Jr., and Bourgoin, A., 1973, Cytoplasmic antigens in human malignant melanoma cells, in: Pigment Cell Mechanisms in Pigmentation (V. G. McGovern and P. Russell Sidney (eds.). Int. Pigm. Cell. Conf, Vol. 1, pp. 366–371, S. Karger, Basel.Google Scholar
  9. Bowen, J. M., McBride, C. M., Miller, M. F., and Dmochowski, L., 1976, The relationship of nucleolar antigens in malignant melanoma cells to disease prognosis, Pigm. Cell 2:174.Google Scholar
  10. Bucana, C., and Hanna, H. M., 1974, Immunoelectron microscopic analysis of surface antigens common to Mycobacterium bonis (BCG) and tumor cells, J. Natl. Cancer Inst. 53:1313.PubMedGoogle Scholar
  11. Butterworth, C., Oon, C. T., Westburg, G., and Hobbs, J. R., 1974, T-lymphocyte responses in patients with malignant melanoma, Eur. J. Cancer 10:639.PubMedGoogle Scholar
  12. Bystryn, J.-C., and Smalley, J. R., 1977, Identification and solubilizaton of iodinated cell surface human melanoma associated antigens, Int. J. Cancer 20:165.PubMedGoogle Scholar
  13. Bystryn, J.-C., and Smalley, J. R., 1978, Purification of a cell-surface human melanoma associated antigen (MAA), Clin. Res. 26:432A.Google Scholar
  14. Canevari, S., Fossati, G., Della Porta, G., and Balzanni, G. P. 1975, Humoral cytotoxicity in melanoma patients and its correlation with the extent and the course of the disease, Int. J. Cancer 16:722.PubMedGoogle Scholar
  15. Canevari, S., Fossati, G., and Della Porta, G., 1976, Cellular immune reaction to human malignant melanoma and breast carcinoma cells, J. Natl. Cancer Inst. 56:705.Google Scholar
  16. Carey, T., Takahashi, T., Resnick, L. A., Oettgen, H. F., and Old, L. J., 1976, Cell surface antigen to human malignant melanoma. I. Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells, Proc. Natl. Acad. Sci. U.S.A. 73:3278.PubMedGoogle Scholar
  17. Carey, T. E., Lloyd, K. O., Takahashi, T., Travassos, L. R., and Old, L. J., 1979, AU cell-surface antigen of human malignant melanoma: Solubilization and partial characterization, Proc. Natl. Acad. Sci. U.S.A. 76:2898.PubMedGoogle Scholar
  18. Carrel, S., and Theilkaes, L., 1973, Evidence for tumor-associated antigen in human malignant melanoma, Nature (London) 242:609.Google Scholar
  19. Carrel, S., Accolla, R. S., Carmgnola, A. L., and Mach, J. P. 1980, Common human melanoma-associated antigen(s) detected by monoclonal antibodies, Cancer Res. 40:2523.PubMedGoogle Scholar
  20. Catalona, W. L., Sample, W. F., and Chretien, P. B., 1973, Lymphocyte reactivity in cancer patients: Correlation with tumor histology and clinical stage, Cancer 31:65.PubMedGoogle Scholar
  21. Char, D. M., Hollinshead, A., Cogan, D. G., Ballintine, E. J., Hogan, M. J., and Herberman, R. B., 1974, Cutaneous delayed hypersensitivity reactions to soluble melanoma antigen in patients with ocular malignant melanoma, N. Engl. J. Med. 291:274.PubMedGoogle Scholar
  22. Chee, D. O., and Gupta, R. K., 1980, Tumor immunology and chemical carcinogenesis, in: Genetic Differences in Chemical Carcinogenesis (R. E. Kouri, ed.), pp. 151–184, CRC Press, Boca Raton, Florida.Google Scholar
  23. Chee, D. O., Boddie, A. W., Jr., Roth, J. A., Holmes, E. C., and Morton, D. L., 1976, Production of melanoma-associated antigen by a human malignant melanoma cell strain grown in chemically defined medium, Cancer Res. 36:1505.Google Scholar
  24. Cheng, L. Y., Gupta, R. K., Huth, J. F., and Morton, D. L., 1981, Characterization of urinary antigen detected in melanoma patients by autologous and allogeneic antibody, Proc. Am. Assoc. Cancer Res. 22:292Google Scholar
  25. Cochran, A. J., Mackie, R. M., Grant, R. M., Ross, C. E., Connell, M. D., Sandilands, G., Whaley, K., Hoyle, D. E., and Jackson, A. M., 1976, An examination of cancer patients, Int. J. Cancer 18:298.PubMedGoogle Scholar
  26. Coombs, R. R. A., Daniel, M. R., Gurner, B. W., and Kelus, A., 1961. Recognition of the species of cell origin in culture by mixed agglutination. II. Use of heterophile (anti-Forssman) sera, Int. Arch. Allergy 19:210Google Scholar
  27. Copeman, P. W., 1979, Significance of melanoma antigen (melanoma specific protein) in the urine, J. R., Soc. Med. 72:95.Google Scholar
  28. Cornain, S., deVries, J. E., Collard, J., Vennegoor, C., Wingerden, I. V., and Rumke, P., 1975, Antibodies and antigen expression in human melanoma detected by the immune adherence test, Int. J. Cancer 16:981PubMedGoogle Scholar
  29. Currie, A., 1973, Circulating antigen as an inhibitor of tumor immunity in man, Br. J. Cancer 28(1):153Google Scholar
  30. Currie, G., and Basham, C., 1972, Serum mediated inhibition of the immunologic reactions of the patients to his own tumor: A possible role for circulating antigen, Br. Med. J. 26:427.Google Scholar
  31. DeKernion, J. B., Golub, S. H., Gupta, R. K., Silverstein, M. J., and Morton, D. L., 1975, Successful trans-urethral intralesional BCG therapy of a bladder melanoma, Cancer 36:1661.Google Scholar
  32. Della Porta, G., Calvari, S., Della Torre, G., Fossati, G., Pierotti, M. A., Vezzoni, P., and Vaglini, M., 1979, Skin test for delayed hypersensitivity to cancer extracts in cancer patients, in: Current Trends in Tumor Immunology (S. Ferrone, S. Gorini, R. B. Herberman, and R. A. Reisfeld, eds.), pp. 85–92, Garland STM Press, New York.Google Scholar
  33. Dent, P. B., Liao, S. K., McCulloch, P. B., Blajchman, M. A., and Macnamera, J., 1978, Characterization of human malignant melanoma cell lines. III. Membrane immunofluorescence reactivity with sera from patients with melanoma, Cancer Immunol. Immunother. 3:239.Google Scholar
  34. DeVries, J. E., Rumke, P., and Berneheim, J. L., 1972, Cytotoxic lymphocytes in melanoma patients, Int. J. Cancer 9:567.Google Scholar
  35. Eilber, F. R., and Morton, D. L., 1970, Impaired immunologic reactivity and recurrence following cancer surgery, Cancer 25:362.PubMedGoogle Scholar
  36. Eilber, F. R., Nizze, J. A., and Morton, D. L., 1975, Sequential evaluation of general immune competence in cancer patients: Correlation with clinical course, Cancer 35:660.PubMedGoogle Scholar
  37. Eilber, F. R., Morton, D. L., Holmes, E. C., Sparks, F. C., and Ramming, K. P., 1976, Adjuvant immunotherapy with BCG in treatment of regional lymph node metastases from malignant melanoma, N. Engl. J. Med. 294:237.PubMedGoogle Scholar
  38. Elliott, P. G., Turlow, B., Needham, P. R. G., and Lewis, M. G., 1973, The specificity of cytoplasmic antigen in human malignant melanoma, Eur. J. Cancer 9:606.Google Scholar
  39. Embleton, M. J., and Price, M. R., 1975, Inhibition of in vitro lymphotoxic reactions against tumor cell by melanoma membrane extracts, Behring Inst. Mitt. 56:157.Google Scholar
  40. Engvall, E., and Perlmann, P., 1971, Enzyme linked immusorbent assay (ELISA): Quantitative assay of IgG, Immunochemistry 8:871.PubMedGoogle Scholar
  41. Everson, T. C., and Cole, W. H., 1966, Spontaneous Regression of Cancer, W. B. Saunders, Philadelphia. Fass, L., Herberman, R. B., Ziegler, J. L., and Kiryabwire, J. W. M., 1970. Cutaneous hypersensitivity reactions to autologous extracts of malignant melanoma cells, Lancet 1:116.Google Scholar
  42. Ferrone, S., and Pellegrino, M. A., 1977, Cytotoxic antibodies to cultured melanoma cells in sera of melanoma patients, J. Natl. Cancer Inst. 58:1201.PubMedGoogle Scholar
  43. Ferrone, S., and Pellegrino, M. A., 1979, Serological detection of human melanoma associated antigens, in: Immunodiagnosis of Cancer (R. B. Herberman and K. R. McIntire, eds.), pp. 588–632, Marcell Dekker, New York.Google Scholar
  44. Fossati, G., Colnaghi, M. I., and Della Porta, G., 1971, Cellular and humoral immunity against human malignant melanoma, Int. J. Cancer 8:344.PubMedGoogle Scholar
  45. Gallaway, D. R., McCabe, R. P., Pellegrino, M. A. Ferrone, S., and Reisfeld, R. A., 1979, Molecular profile of human melanoma-associated antigens purified from spent culture medium, Fed Proc. Fed. Am. Soc. Exp. Biol. 38:1105.Google Scholar
  46. Gallaway, D. R., Walker, L. E., and Ferrone, S., 1980, Isolation and characterization of human tumor-associated antigens with monoclonal antibody, Proc. Am. Assoc. Cancer Res. 21:25.Google Scholar
  47. Gallaway, D. R., McCabe, R. P., Pellegrino, M. A., Ferrone, S., and Reisfeld, R. A., 1981, Tumor-associated antigens in spent culture medium of human melanoma cells: Immunochemical characterization with xenoantisera, J. Immunol. 126:62.Google Scholar
  48. Gatti, R. A., and Good, R. A., 1971, Occurrence of malignancy in immunodeficiency diseases, Cancer 28:89. Ghose, T., Norvell, S. T., Guclu, A., and McDonald, A. S., 1975, Immunochemotherapy of human malignant melanoma with chlorambucil-carrying antibody, Eur. J. Cancer 11:321.Google Scholar
  49. Glasgow, A. H., Nimberg, R. B., Menzoian, J. O., Sporaschetz, I., Cooperband, S. R., Schmidt, K., and Mannik, J. A., 1974, Association of energy with an immunosuppressive peptide fraction in serum of patients with cancer, N. Engl. J. Med. 291:1263.PubMedGoogle Scholar
  50. Golub, S. H., O’Connell, T. X., and Morton, D. L., 1974, Correlation of in vivo and in vitro assays of immunocompetence in cancer patients, Cancer Res. 34:1833.PubMedGoogle Scholar
  51. Golub, S. H., Rangel, D. M., and Morton, D. L., 1977, In vitro assessment of immunocompetence in patients with malignant melanoma, Int. J. Cancer 20:873.PubMedGoogle Scholar
  52. Gray, B. R., Mehigan, J. T., and Morton, D. L., 1971, Demonstration of antibodies in melanoma patients cytotoxic to human melanoma cells, Proc. Am. Assoc. Cancer Res. 12:79.Google Scholar
  53. Griffith, J. D., McKinna, J. A., Rowbatham, H. D., Tsolakidis, P., and Salsbury, A. J., 1973, Carcinoma of the colon and rectum: Circulating malignant cells and five-year survival, Cancer 31:226.Google Scholar
  54. Grimm, E. A., Silver, H. K. B., Roth, J. A., Chee, D. O., Gupta, R. K., and Morton, D. L., 1976, Detection of tumor associated antigen in human melanoma cell line supernatants, Int. J. Cancer 17:559.PubMedGoogle Scholar
  55. Giuliano, A. E., Rangel, D. M., Holmes, E. C., Golub, S. H., and Morton, D. L., 1977, Serum-mediated immunosuppression in cancer, Surg. Forum 28:163.PubMedGoogle Scholar
  56. Gupta, R. K., 1975, Common cancer associated antigen(s) in human neoplasms, Proc. Am. Assoc. Cancer Res. 15:262.Google Scholar
  57. Gupta, R. K., 1980, Antigenic complexity in human malignant melanoma tumors detected by allogeneic antibody, in: Serologic Analysis of Human Cancer Antigens (S. A. Rosenberg, ed.), pp. 339–380, Academic Press, New York.Google Scholar
  58. Gupta, R. K., and Morton, D. L., 1975a, Suggestive evidence for in vivo binding of specific antitumor antibodies of human melanomas, Cancer Res. 35:58.Google Scholar
  59. Gupta, R. K., and Morton, D. L., 1975b, Presence of tumor-associated antigens in urine of patients with cancer, Surg. Forum 26:158.Google Scholar
  60. Gupta, R. K., and Morton, D. L., 1976, Tumor-associated antigens in urine of cancer patients, Proc. Am. Assoc. Cancer Res. 17:92.Google Scholar
  61. Gupta, R. K., and Morton, D. L., 1977, Distribution of antibodies to common tumor-associated antigen(s) in cancer and non-cancer sera, Proc. Am. Assoc. Cancer Res. 18:184.Google Scholar
  62. Gupta, R. K., and Morton, D. L., 1979a, Double antibody method and the protein-A bearing Staphylococcus aureus cells method compared for separating bound and free antigen in radioimmunoassay, Clin. Chem. 25:752.Google Scholar
  63. Gupta, R. K., and Morton, D. L. 1979b, Detection of cancer-associated antigens in urine of sarcoma patients, J. Surg. Oncol. 11:65.Google Scholar
  64. Gupta, R. K., and Morton, D. L., 1979c, Specificity by radioimmunoassay of tumor-associated antigen isolated from spent culture medium of a human melanoma cell line, Fed. Proc. Fed. Am. Soc. Exp. Biol. 39:1144.Google Scholar
  65. Gupta, R. K., and Morton, D. L., 1980, Radioimmunoassay for the analysis of tumor associated antigens with allogeneic antibody, in: Serologic Analysis of Human Cancer Antigens (S. A. Rosenberg, ed.), pp. 645–650, Academic Press, New York.Google Scholar
  66. Gupta, R. K., Irie, R. F., and Morton, D. L., 1978a, Antigens on human tumor cells assayed by complement fixation with allogeneic antisera, Cancer Res. 38:2573.Google Scholar
  67. Gupta, R. K., Silver, H. K. B., and Morton, D. L., 19786, Reactivity of human tumor extracts to xenogeneic antisera raised against human melanoma extracts, Proc. Am. Assoc. Cancer Res. 19:360.Google Scholar
  68. Gupta, R. K., Golub, S. H., and Morton, D. L., 1979a, Correlation between tumor burden and anticomple-mentary activity in sera from cancer patients, Cancer Immunol. Immunother. 6:63.Google Scholar
  69. Gupta, R. K., Golub, S. H., Rangel, D. M., and Morton, D. L., 1979b, Inhibition of mitogen-induced lymphocyte proliferation correlated to anticomplementary activity in sera from melanoma patients, Cancer Immunol. Immunother. 5:221.Google Scholar
  70. Gupta, R. K., Irie, R. F., Chee, D. O., Kern, D. H., and Morton, D. L., 1979c, Demonstration of two distinct antigens in spent tissue culture medium of a human malignant melanoma cell line, J. Natl. Cancer Inst. 63:347.Google Scholar
  71. Gupta, R. K., Silver, H. K. B., Reisfeld, R. A., and Morton, D. L., 1979d, Isolation and immunochemical characterization of antibodies from cancer patients’ sera reactive against human melanoma cell membranes by affinity chromatography, Cancer Res. 39:1683.Google Scholar
  72. Gupta, R. K., Theofilopoulos, A. N., Dixon, F. J., and Morton, D. L., 1979e, Circulating immune complexes as possible cause for anticomplementary activity in humans with maligant melanoma, Cancer Immunol. Immunother. 6:211.Google Scholar
  73. Gupta, R. K., Silver, H. K. B., and Morton, D. L., 1980, Production and characterization of xenogeneic antisera to tumor-associated antigen(s), J. Surg. Oncol. 13:75.PubMedGoogle Scholar
  74. Hamburger, R. N., Pioris, D. A., and Milles, S. E., 1963, Antigenic specificities acquired from the growth medium by cells in tissue culture, Immunology 6:439.PubMedGoogle Scholar
  75. Hellström, I., Sjögren, H. O., Warner, G. A., and Hellström, K. E., 1971, Blocking of cell mediated tumor immunity by sera from patients with growing neoplasms, Int. J. Cancer 7:226.PubMedGoogle Scholar
  76. Hellström, I., Hellström, K. E., Sjögren, H. O., and Warner, G. A., 1973a, Destruction of cultivated melanoma cells by lymphocytes from healthy black (North American Negro) donors, Int. J. Cancer 11:116.Google Scholar
  77. Hellström, I., Warner, G. A., Hellström, K. E., and Sjögren, H. O., 1973b, Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma, Int. J. Cancer 11:280.Google Scholar
  78. Hellström, I., Brown, J. P., Woodbury, R., Yen, Y. M., Nishiyama, K., and Hellström, K. E., 1980, Mono-clonal antibodies to tumor-associated antigens in human melanoma, Proc. Am. Assoc. Cancer Res. 21:221Google Scholar
  79. Hellström, K. E., and Hellström, I., 1974, Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens, Ada. Immunol. 18:209.Google Scholar
  80. Hellström, K. E., and Hellström, I., 1977, Immunologic enhancement of tumor growth, in: Mechanisms of Tumor Immunity (I. Green, S. Cohen, and R. T. McCluskey, eds.). pp. 147–191, Wiley, New York.Google Scholar
  81. Heppner, G. H., Stolbach, L., Byrne, M., Cummings, F. J., McDonough, E., and Calabrest, E., 1973, Cell- mediated reactivity to tumor antigens in patients with malignant melanoma, Int. J. Cancer 11:245.PubMedGoogle Scholar
  82. Hersey, P., Honeyman, M., Edwards, A., Adams, E., and McCarthy, W. H., 1976, Antigens on melanoma cells detected by leukocyte dependent antibody assays of human melanoma antisera, Int. J. Cancer 18:564.PubMedGoogle Scholar
  83. Hersey, P., Murray, E., and Ruygrok, S., 1978, Characterization of melanoma antigens in sera of melanoma patients and in supernatants of melanoma cell cultures, Fed. Proc. Fed. Am. Soc. Exp. Biol. 37:1595.Google Scholar
  84. Hersey, P., Murray, E., Werkmeister, J., and McCarthy, W. H., 1979, Detection of a low molecular weight antigen on melanoma cells by a human antiserum in leukocyte-dependent antibody assay, Br. J. Cancer 40:615.PubMedGoogle Scholar
  85. Hollinshead, A. C., Herberman, R. B., Jaffurs, W. J., Alpert, L. K., Minten, J. P., and Harris, J. E., 1974, Soluble membrane antigens of human maligant melanoma cells, Cancer 34:1235.PubMedGoogle Scholar
  86. Holmes, E. C., Roth, J. A., and Morton, D. L., 1975, Delayed cutaneous hypersensitivity reactions to autologous extracts of malignant melanoma cells, Surgery 78:160.PubMedGoogle Scholar
  87. Huth, J. F., Gupta, R. K., and Morton, D. L., 1979, Sequential analysis of urinary antigens in sarcoma patients, Surg. Forum 30:150.PubMedGoogle Scholar
  88. Huth, J. F., Gupta, R. K., and Morton, D. L., 1981a, Development of an enzyme immunoassay to detect and quantitate tumor-associated antigens in the urine of sarcoma patients, Cancer 47:28–56.Google Scholar
  89. Huth, J. F., Gupta, R. K., and Morton, D. L., 1981b, Assessment of the in vivo effectiveness of tumoricidal chemotherapy and radiation therapy by serial analysis of tumor-associated urinary antigen titers in sarcoma patients, Cancer Treatment Rep. (in press).Google Scholar
  90. Irie, R. F., 1980, Oncofetal antigen (OFA-I): A human tumor associated fetal antigen immunogenic in man, in: Serologic Analysis of Human Cancer Antigens (S. A. Rosenberg, ed.), pp. 493–513, Academic Press, New York.Google Scholar
  91. Irie, R. F., Irie, K., and Morton, D. L., 1974a, Natural antibody in human serum to a neoantigen in human cultured cells grown in fetal bovine serum, J. Natl. Cancer Inst. 52:1051.Google Scholar
  92. Irie, R. F., Irie, K., and Morton, D. L., 19746, Characteristics of heterologous membrane antigen on cultured human cells, J. Natl. Cancer Inst. 53:1545.Google Scholar
  93. Irie, R. F., Irie, K., and Morton, D. L., 1976, A membrane antigen common to human cancer and fetal brain tissues, Cancer Res. 36:3510.PubMedGoogle Scholar
  94. Jehn, V. W., Nathanson, L., Schwartz, R. S., and Skinner, M., 1970, In vitro lymphocyte stimulation of a soluble antigen from malignant melanoma, N. Engl. J. Med. 283:329.Google Scholar
  95. Jose, D. G., and Seshadri, R., 1974, Circulating immune complexes in human neuroblastoma: Direct assay and role in blocking specific cellular immunity, Int. J. Cancer 13:824.PubMedGoogle Scholar
  96. Kasai, M., Saxton, R. E., Holmes, E. C., Burk, W. M., and Morton, D. L., 1981, Membrane antigens detected on human lung carcinoma cells by hybridoma monoclonal antibody, J. Surg. Res. 30:403.PubMedGoogle Scholar
  97. Kilburn, D. G., Fairhurst, M., Levey, J. G., and Whitney, R. B., 1976, Synergism between immune complexes and serum from tumor-bearing mice in the suppression of mitogen responses, J. Immunol. 117:1612PubMedGoogle Scholar
  98. Koprowski, H., Steplewski, Z., Herlyn, D., and Herlyn, M., 1978, Studies of antibodies against human mel-anoma produced by somatic cell hybrid, Proc. Natl. Acad. Sci U.S.A. 75:3405.Google Scholar
  99. Laine, R. A., and Kakorman, A., 1973, Incorporation of exogenous glycosphingolipid in plasma membranes of cultured hamster cells and concurrent change of growth behavior, Biochim. Biophys. Acta 54:1039.Google Scholar
  100. Lee, Y. T. N., Sparks, F. C., Eilber, F. R., and Morton, D. L., 1975, Delayed cutaneous hypersensitivity and peripheral lymphocyte counts in patients with advanced cancer, Cancer 35:748.PubMedGoogle Scholar
  101. Leong, S. P., Cooperband, S. R., Sutherland, C. M., Krementz, E. T., and Deckers, P. J., 1978a, Detection of human melanoma antigens in cell-free supernatants, Biochem. Med. 24:245.Google Scholar
  102. Leong, S. P., Cooperband, S. R., Deckers, P. J., Sutherland, C. M., and Krementz, E. T., 1978b, Isolation of human melanoma membrane antigens, Clin. Res. 26:224A.Google Scholar
  103. Lewis, M G., and Kiryabwire, J. W. M., 1968, Aspects of behavior and natural history of malignant melanoma in Uganda, Cancer 21:876.PubMedGoogle Scholar
  104. Lewis, M G., and Phillips, T. M., 1972, Specificity of surface membrane immunofluorescence in human malignant melanoma, Int. J. Cancer 10:105.PubMedGoogle Scholar
  105. Lewis, M G., Ikonopisov, R. L., Nairn, R. C., Phillips, T. M., Hamilton-Fairley, G., Bodenham, D. C., and Alexander, P., 1969, Tumour specific antibodies in human malignant melanoma and their relationship to the extent of the disease, Br. Med. J. 3:547.PubMedGoogle Scholar
  106. Lewis, M.G., Phillips, T. M., Cook, K. B., and Blake, J., 1971, Possible explanation for loss of detectable antibody in patients with disseminated malignant melanoma, Nature (London) 232:52.Google Scholar
  107. Lewis, M. G., Avis, P. J. G., Phillips, T. M., and Sheikh, K. M. A., 1973, Tumor-associated antigens in human malignant melanoma, Yale, J. Biol. Med. 46:661.Google Scholar
  108. Liao, S. K., Leong, S. P. L., Sutherland, C. M., Dent, P. B., Kwong, D. C., and Krementz, E. T., 1978, Common human melanoma membrane antigens detected by mixed hemadsorption assay with sera from a patient undergoing immunotherapy with autologous tumor cells, Cancer Res. 38:4394.Google Scholar
  109. Lopez, M J., and Thomson, D. M. P., 1977, Isolation of breast tumor antigen from serum and urine, Int. J. Cancer 20:834.PubMedGoogle Scholar
  110. Macher, E., Muller, C., Sorg, G., Gassen, A., and Sorg, C., 1975, Evidence for cross-reacting membrane-associated specific melanoma antigens as detected by immunofluorescence and immune adherence, Behring Inst. Mitt 56:86.Google Scholar
  111. Malley, A., Frikke, M. J., Burger, D. R., Black, J. A., and Vandenbark, A. A., 1976, Fractionation of human melanoma tumor antigens, Fed. Proc. Fed. Am. Soc. Exp. Biol. 35:547.Google Scholar
  112. McBride, C. M., Bowen, J. M., and Dmochowski, L. L., 1972, Anti-nucleolar antibodies in the sera of patients with malignant melanoma, Surg. Forum 23:92.PubMedGoogle Scholar
  113. McCabe, R. P., Ferrone, S., Pellegrino, M. A., Kern, D. H., Homes, E. C., and Reisfeld, R. A., 1978a, Purification and immunological evaluation of human melanoma associated antigens, J. Natl. Cancer Inst. 60:773.Google Scholar
  114. McCabe, R. P., Frugis, L., Ferrone, S., Kern, D., and Reisfeld, R. A., 1978, Detection and purification of human melanoma-associated cell surface antigens, Proc. Am. Assoc. Cancer Res. 19:206.Google Scholar
  115. McCabe, R. P., Quaranta, V., Frugis, L., Ferrone, S., and Reisfeld, R. A., 1979, A radioimmunometric antibody binding assay for the evaluation of xenoantisera to melanoma associated antigens, J. Natl. Cancer Inst. 62:455.PubMedGoogle Scholar
  116. McKhann, C. F., 1969, Primary malignancy in patients undergoing immunosuppression for renal transplantation, Transplantation 8:209.PubMedGoogle Scholar
  117. Minden, P., Sharpton, T. R., and McClatchy, J. K., 1976, Shared antigens between human malignant melanoma cells and Mycobacterium bovis (BCG), J. Immunol. 116:1407.PubMedGoogle Scholar
  118. Moretta, L., Webb, S. R., Girossi, C. E., Lydyard, T. M., and Cooper, M D., 1977, Functional analysis of two human T-cell subpopulations: Help and supression of B-cell responses by T-cell bearing receptors for IgM and IgG, J. Exp. Med. 146:184.PubMedGoogle Scholar
  119. Morton, D. L., 1971, Immunologic studies with human neoplasms, J. Reticuloendothel. Soc. 10:137.PubMedGoogle Scholar
  120. Morton, D. L., Malmgren, R. A., Holmes, E. C., and Ketcham, A. S., 1968, Demonstration of antibodies against human malignant melanoma by immunofluorescence, Surgery 64:233.PubMedGoogle Scholar
  121. Morton, D. L., Eilber, F. R., Malmgren, R. A., and Wood, W. C., 1970, Immunologic factors which influence response to immunotherapy in malignant melanoma, Surgery 68:158.PubMedGoogle Scholar
  122. Morton, D. L., Eilber, F. R., and Malmgren, R. A., 1971a, Immune factors in human cancer: Malignant melanomas, skeletal and soft tissue sarcomas, Prog. Exp. Tumor Res. 14:25.Google Scholar
  123. Morton, D. L., Holmes, E. C., Eilber, F. R., and Wood, W. C., 1971b, Immunologic aspects of neoplasia: A rational basis for immunotherapy, Ann. Intern. Med. 74:587.Google Scholar
  124. Morton, D. L., Golub, S. H., Sulit, H. L., Gupta, R. K., Eilber, F. R., Holmes, E. C., and Sparks, F. C., 1975, Immunologic and clinical responses to active immunotherapy of malignant melanoma, in: Fundamental Aspects of Neoplasia (A. A. Gottlieb, O. J. Plescia, and D. H. L. Bishop, eds.), pp. 181–201, Springer-Verlag, New York.Google Scholar
  125. Mukherji, B., Nathanson, L., and Clark, D. A., 1973, Studies of humoral and cell-mediated immunity in human melanoma, Yale J. Biol. Med. 46:681.PubMedGoogle Scholar
  126. Muna, N. M., Marcus, S., and Smart, C., 1969, Dectection by immunofluorescence of antibodies specific for human malignant melanoma cells, Cancer 23:88.PubMedGoogle Scholar
  127. Nairn, R. C., Nind, A. P., Guli, E. P., Davies, K. J., Little, J. H., Davies, N. C., and Whitehead, R. H., 1972, Anti-tumor immunoreactivity in patients with malignant melanoma, Med. J. Aust. 1:397PubMedGoogle Scholar
  128. Nathanson, L., 1974, Use of BCG in the treatment of human neoplasms: A review, Semin. Oncol. 1:337.PubMedGoogle Scholar
  129. Nelson, D. S., and Gatti, R. A., 1976, Humoral factors influencing lymphocyte transformation, Prog. Allergy 21:261.PubMedGoogle Scholar
  130. Oettgen, H. F., Aoki, T., Old, L. J., Boys, E. A., deHarven, E., and Mills, G. M., 1968, Suspension culture of a pigment-producing cell line derived from a human malignant melanoma, J. Natl. Cancer Inst. 41:827PubMedGoogle Scholar
  131. Oettgen, H. F., Pinsky, C. M., and Delmonte, L., 1976, Treatment of cancer with immunomodulators: Coryn-ebacterium parvum and Levamisole, Med. Clin. North Am. 60:511.PubMedGoogle Scholar
  132. Oren, M. E., and Herberman, R. B., 1971, Delayed cutaneous hypersensitivity reactions to membrane extracts of human tumor cells, Clin. Exp. Immunol. 9:45.PubMedGoogle Scholar
  133. Parikh, I., March, S., and Cuatrecasas, P., 1974, Topics in the methodology of substitution reactions with agarose, in: Methods in Enzymology, Vol. 34 (Part B) (W. B. Jakoby and M. Wilchek, eds.), pp. 77–102, Academic Press, New York.Google Scholar
  134. Peacock, A. C., and Dingman, C. W., 1968, Molecular weight estimation and separation of ribonucleic acid by electrophoresis in agarose-acrylamide composite gels, Biochemistry 7:668.PubMedGoogle Scholar
  135. Penn, I., 1970, Chemical immunosuppression and human cancer, Cancer 34:1474.Google Scholar
  136. Penn, I., Hammond, W., Brettschmeider, L., and Sturzl, T. E., 1969, Malignant lymphomas in transplantation patients, Transplant. Proc. 1:106.PubMedGoogle Scholar
  137. Peter, H. H., Pavie-Fischer, J., Fridman, W., Aubert, C., Cesarini, J. P., Roubin, R., and Kounilsky, F., 1975, Cell-mediated cytoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (1GR3), J. Immunol. 115:539.PubMedGoogle Scholar
  138. Peterson, R. D. A., Kelly, W. D., and Good, R. A., 1964, Ataxia telangiectasia: Its association with defective thymus, immunological-deficiency diseases and malignancy, Lancet 1:1189.PubMedGoogle Scholar
  139. Pilch, Y. H., Fritze, D., and Kern, D. H., 1976, Immune RNA in the immunotherapy of cancer, Med. Clin. North Am. 60:567.PubMedGoogle Scholar
  140. Pinsky, C., Hirshaut, Y., and Oettgen, H., 1972, Treatment of malignant melanoma by intratumoral injection of BCG, Proc. Am. Assoc. Cancer Res. 13:21.Google Scholar
  141. Ran, M., Klein, G., and Witz, I. P., 1976, Tumor bound immunoglobulins: Evidence for the in vivo coating of tumor cells by potentially cytotoxic anti-tumor antibodies, Int. J. Cancer 17:90.PubMedGoogle Scholar
  142. Rangel, D. M., Golub, S. H., and Morton, D. L., 1977, Demonstration of lymphocyte blastogenesis-inhibiting factors in sera of melanoma patients, Surgery 82:224.PubMedGoogle Scholar
  143. Reisfeld, R. A., Pellegrino, M. A., and Kahan, B. D., 1971, Salt extraction of soluble HL-A antigens, Science 172:1134.PubMedGoogle Scholar
  144. Reisfeld, R. A., McCabe, R. P., Ferrone, S., Pellegrino, M. A., and Holmes, E. C., 1977, Characterization of melanoma associated antigens isolated from cultured melanoma cells, Proc. Am. Assoc. Cancer Res. 18:205Google Scholar
  145. Ristow, S., and McKhann, C. F., 1977, Tumor-associated antigens, in: Mechanisms of Tumor Immunity (I.Green, S. Cohen, and R. T. McClusky, eds.), pp. 109–145, John Wiley, New York.Google Scholar
  146. Roberts, S. S., Hengesh, J. W. McGrath, R. G., Valaitis, J., McGrew, E. A., and Cole, W. H., 1967, Prog-nostic significance of cancer cells in circulating blood: A ten year evaluation, Am. J. Surg. 113:757PubMedGoogle Scholar
  147. Romsdahl, M. M., and Cox, I. S., 1970, Human malignant melanoma antibodies demonstrated by immunoflu-orescence, Arch. Surg. 100:491.PubMedGoogle Scholar
  148. Romsdhal, M. M., and Cox, I. S., 1973, Immunological studies on malignant melanomas of man, Yale J. Biol. Med. 46:693.Google Scholar
  149. Rosenberg, E. B. McCoy, J. L., Green, S. S., Donnelly, F. C., Siwarski, D. F., Levine, P. H., and Herberman, R. B., 1974, Destruction of human lymphoid tissue-culture cell line by human peripheral blood lymphocytes in 51Cr-release cellular cytotoxicity assays, J. Natl. Cancer Inst. 52:345.PubMedGoogle Scholar
  150. Rote, N. S., Gupta, R. K., and Morton, D. L., 1978, Detection of tumor-associated antigens in the urine of sarcoma patients Proc. Am. Assoc. Cancer Res. 19:134.Google Scholar
  151. Rote, N. S., Gupta, R. K., and Morton, D. L., 1980a, Determination of incidence of tumor-associated antigens found in the urine of patients bearing solid tumors, Int. J. Cancer 26:203Google Scholar
  152. Rote, N. S., Gupta, R. K., and Morton, D. L., 1980b, Tumor-associated antigens detected by autologous sera in urine of patients with solid neoplasms, J. Surg. Res. 29:18.Google Scholar
  153. Roth, J. A., Slocum, H.K., Pellegrino, M A., Holmes, E. C., and Reisfeld, R. A., 1976, purification of soluble melanoma-associated antigens, Cancer Res. 36:2360.PubMedGoogle Scholar
  154. Saxton, R. E., Golub, S. H., and Morton, D. L., 1978, Specificity of antibody induced in sarcoma patients immunized with allogeneic sarcoma cells, Proc. Am. Assoc. Cancer Res. 19:135.Google Scholar
  155. Seibert, E., Sorg, C., Happle, R., and Macher, E., 1977, Membrane associated antigens of human malignant melanoma. III. Specificity of human sera reacting with cultured melanoma cells, Int. J. Cancer 19: 172.PubMedGoogle Scholar
  156. Seigler, H. F. Shingleton, W. W., Metzgar, R. D., Buckley, C. E., Bergoc, C. M., Miller, D. S., Fatter, B. F., and Phaup, M. B., 1972, Non-specific and specific immunotherapy in patients with melanoma, Surgery 72:162.PubMedGoogle Scholar
  157. Seigler, H. F., Metzgar, R. S., Mohankumar, T., and Stuhlmiller, G. M., 1975a, Human melanoma and leukemia-associated antigens defined by non-human primate antisera, Fed. Proc. Fed. Am. Soc. Exp. Biol. 34:1642.Google Scholar
  158. Seigler, H. F., Shingleton, W. W., Home, B. J., and Pickness, K. L., 1975b, The use of BCG, adoptive transfer, and neuraminidase treated cells in the management of melanoma, Behring Inst. Mitt. 56:214.Google Scholar
  159. Shibata, H. R., Jerry, L. M., Lewis, M. G., Manself, P. W. A., Capek, C., and Marquis, G., 1976, Immunotherapy of malignant melanoma with irradiated tumor cells, oral bacillus Calmette-Guérin and levamisole, Ann. N.Y. Acad. Sci. 277:355.PubMedGoogle Scholar
  160. Shiku, H., Takahashi, T., Oettgen, H. F., and Old, L. J., 1976, Cell surface antigen of human malignant melanoma. II. Serologic typing with immune adherence assays and definition of two new surface antigens, J. Exp. Med. 144:873.PubMedGoogle Scholar
  161. Sjögren, H. O., Hellström, I., Bansal, S. C., and Hellström, K. E., 1971, Suggestive evidence that “blocking antibodies” of tumor bearing individuals may be antigen antibody complexes, Proc. Natl. Acad. Sci. U.S.A. 68:1372.PubMedGoogle Scholar
  162. Sjögren, H. O., Hellström, I., Bansal, S. C., Warner, G. A., and Hellström, K. E., 1972, Elution of blocking factors from human tumors capable of abrogating tumor-cell destruction by specifically immune lymphocytes, Int. J. Cancer 9:274.PubMedGoogle Scholar
  163. Smith, W. J., and Jacobs, B. B., 1979, Modification of melanoma antigen expression in vitro, Fed. Proc. Fed. Am. Soc. Exp. Biol. 38:1105.Google Scholar
  164. Sorg, C., Brüggen, J., Seibert, E., and Macher, E., 1978, Membrane associated antigens of human malignant melanoma. IV. Changes in expression of antigens on cultured melanoma cells, Cancer Immunol. Immunother. 3:259.Google Scholar
  165. Southam, C. M., Brunschwig, W., Levin, A. G., and Dixon, Q. S., 1966, The effect of leukocytes on transplantability of human cancer, Cancer 19:1743.PubMedGoogle Scholar
  166. Steel, G., Jr., Ankerst, J., and Sjögren, H. 0., 1974, Alteration of in vitro anti-tumor activity of tumor-bearer sera by absorption with Staphylococcus aureus, Cowan I., Int. J. Cancer 14:83.Google Scholar
  167. Steel, G., Jr. Sjögren, H. O., and Stradenberg, I., 1976, In vitro cell-mediated immune reactions of melanoma and colorectal carcinoma patients demonstrated by long-term ‘Cr assay, Int. J. Cancer 17:27.Google Scholar
  168. Stewart, T. H. M., 1969, The presence of delayed hypersensitivity reactions in patients toward cellular extracts of their malignant tumors, Cancer 23:1368.PubMedGoogle Scholar
  169. Stuhlmiller, G. M., and Seigler, H. F., 1975, Characterization of a chimpanzee anti-human melanoma antiserum, Cancer Res. 35:2132.PubMedGoogle Scholar
  170. Stuhlmiller, G. M., Green, R. W., and Seigler, H. F., 1978, Solubilization and partial isolation of human melanoma tumor-associated antigens, J. Natl. Cancer Inst. 61:61.PubMedGoogle Scholar
  171. Suter, L., Tilkorn, H., and Kovary, P. M., 1978, Human malignant melanoma antigenic properties of phenol water extracts, Arch. Dermatol. Res. 264:37.Google Scholar
  172. Tagasuki, M., Mickey, M. R., and Terasaki, P. I., 1973, Reactivity of lymphocytes from normal persons on cultured tumor cells, Cancer Res. 33:2898.Google Scholar
  173. The, T. H., Huiges, H. A., Koops, H. S., Lambarts, H. B., and Niewg, H. 0., 1975, Surface antigens on cultured malignant melanoma cells as detected by membrane immunofluorescence method with human sera: Lack of tumor specific reaction on melanoma cell lines, Ann. N. Y. Acad. Sci. 254:528.PubMedGoogle Scholar
  174. Theofilopoulos, A. N., and Dixon, F. J., 1978, Immune complexes associated with neoplasia, in: Immunodi-agnosis of Cancer Part 2 (R. B. Herberman, ed.), pp. 896–937, Marcel Dekker, New York.Google Scholar
  175. Thomson, D. M. P., and Lopez, M. J., 1978, Isolation of human tumor antigen from serum and urine, Proc. Am. Assoc. Cancer Res. 19:171.Google Scholar
  176. Thomson, D. M. P., Steel, K., and Alexander, P., 1973, The presence of tumorspecific membrane antigen of a chemically induced sarcomata, Br. J. Cancer 27:27.PubMedGoogle Scholar
  177. Ting, C. C., and Herberman, R. B., 1976, Humoral host defense mechanisms against tumors, Int. Rev. Exp. Pathol. 15:93.PubMedGoogle Scholar
  178. Tonder, O., Krishnan, E. C., Jewell, W. R., Morse, P. A., and Humphrey, L. J., 1976, Tumor Fc receptors and tumor-associated immunoglobulins, Acta Pathol. Microbiol. Scand. 84:105.Google Scholar
  179. Viza, D., and Phillips, J., 1975, Identification of an antigen associated with malignant melanoma, Int. J. Cancer 16:312.PubMedGoogle Scholar
  180. Volkers, C., Cooke, B., Bennett, C., Byrom, N., Campbell, M., Elliott, P., and Whitfield, P., 1978, The significance of urinary melanoma antigen excretion and the ability of thymosin to raise the level of depleted lymphocytes in vitro in malignant melanoma, Aust. N. Z. J. Surg. 48:32.PubMedGoogle Scholar
  181. Voller, A., Bidwell, D. E., and Bartlett, A., 1976, Microplate enzyme immunoassay for immunodiagnosis of virus infections, in: Manual of Clinical Immunology (N. R. Rose and H. Friedman, eds), pp. 506–512, American Society for Microbiology, Washington, D.C.Google Scholar
  182. Wesenberg, F., 1978, Fc receptors and IgG associated with human malignant tumors Acta Pathol. Microbiol. Scand. 86:259.Google Scholar
  183. Wood, G. W., and Barth, R. F., 1974, Immunofluorescent studies of the serologic reactivity of patients with malignant melanoma against tumor-associated cytoplasmic antigens, J. Natl. Cancer Inst. 53:309.PubMedGoogle Scholar
  184. Yeh, M.-Y., Hellström, I., Brown, J. P., Warner, G. A., Hansen, J. A., and Hellström, K. E., 1979, Cell surface antigens of human melanoma identified by monoclonal antibody, Proc. Natl. Acad. Sci. U.S.A. 76:2927.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Rishab K. Gupta
    • 1
    • 2
  • Donald L. Morton
    • 1
    • 2
  1. 1.Division of Oncology, Department of Surgery, UCLA School of MedicineUniversity of CaliforniaLos AngelesUSA
  2. 2.Surgical ServiceV. A. Medical CenterSepulvedaUSA

Personalised recommendations